Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALENTINE trial (HER3-DXd vs chemotherapy as neoadjuvant therapy in high-risk HR+/HER2- early breast cancer)
2022-001181-36Phase 2Active
- Sponsor
- SOLTI
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of patritumab deruxtecan in breast cancer (3 arms), sponsored by SOLTI. Primary endpoint: Pathologic complete response in breast and lymph nodes (pCRBL). Started Aug 2022; status: active.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-001181-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001181-36.